David Amsellem

Piper Sandler | Healthcare

David Amsellem is an analyst from Piper Sandler specializing in the Healthcare sector. Ranked #1831 out of 4745 analysts, they have issued 47 stock ratings with a success rate of 76.69% and an average return of 24.05%.

David Amsellem has a well-established track record, with 47 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 76.69% and an average return of 24.05%, underscoring their expertise and ability to identify winning opportunities for investors.

#1831

Out of 4745

47

Total Ratings

+76.69%

Success Rate

+24.05%

Average Return

Recent Ratings Analysis

TEVA

Jul 28, 2026

Target

$44.00

Current

$31.67

Performance

0.00%

David Amsellem rated TEVA as Overweight on Jul 28, 2026, setting a price target of 44. Shares have remained stable near 31.67, leaving the 44 target still in play.

ALKS

Jul 28, 2026

Target

$65.00

Current

$50.50

Performance

0.00%

On Jul 28, 2026, ALKS was given a Overweight rating by David Amsellem, with a target price of 65. The stock traded sideways with a 0.00% move, keeping the bullish thesis unresolved.

DFTX

Jul 24, 2026

Target

$73.00

Current

$41.96

Performance

-2.80%

DFTX received a Overweight rating from David Amsellem on Jul 24, 2026, aiming for 73. Price action was muted, as shares hovered around 41.96 despite the bullish outlook.

ABBV

Jun 23, 2026

Target

$298.00

Current

$263.48

Performance

12.23%

On Jun 23, 2026, David Amsellem published a Overweight outlook on ABBV, with a target of 298. Shares gained 12.23%, underscoring the accuracy of the bullish outlook toward 298.

JAZZ

May 22, 2026

Target

$301.00

Current

$256.92

Performance

7.13%

David Amsellem on May 22, 2026 assigned JAZZ a Overweight rating, with a price target of 301. The Buy call aligned well with market performance, producing a gain of 7.13%.

BIIB

May 15, 2026

Target

$225.00

Current

$205.61

Performance

6.56%

On May 15, 2026, David Amsellem reaffirmed BIIB with a Overweight rating, targeting 225. The recommendation was supported by strong follow-through as the stock rose from 205.61 to 205.61.

AMGN

May 14, 2026

Target

$427.00

Current

$393.10

Performance

16.91%

AMGN was rated Overweight by David Amsellem on May 14, 2026, with a price objective of 427. A bullish response from the market helped close the gap of 33.90 to the target.

AMPH

May 11, 2026

Target

$21.00

Current

$20.15

Performance

9.21%

On May 11, 2026, David Amsellem initiated coverage on AMPH with a Neutral rating and target of 21. The Hold stance underestimated the stock’s strength as it gained 9.21%.

NBIX

May 06, 2026

Target

$207.00

Current

$182.83

Performance

24.36%

David Amsellem issued a Overweight recommendation for NBIX on May 06, 2026, price target set at 207. Investors following the Buy call captured upside momentum, with shares now at 182.83.

CORT

May 01, 2026

Target

$88.00

Current

$94.19

Performance

—

On May 01, 2026, CORT was evaluated by David Amsellem, who gave a Overweight rating and target of 88. So far, the Buy call awaits clearer momentum, with shares flat at 94.19.

OGN

Apr 28, 2026

Target

$14.00

Current

$13.52

Performance

1.50%

David Amsellem rated OGN as Neutral on Apr 28, 2026, setting a price target of 14. The Hold stance appears justified, as shares hovered around 13.52 with a 1.50% move.

PTHS

Feb 27, 2026

Target

$48.00

Current

$27.77

Performance

5.35%

On Feb 27, 2026, PTHS was given a Overweight rating by David Amsellem, with a target price of 48. The stock rallied 5.35% after the rating, narrowing the gap to the target of 48 and validating the bullish stance.

BMY

Feb 23, 2026

Target

$75.00

Current

$63.60

Performance

3.84%

BMY received a Overweight rating from David Amsellem on Feb 23, 2026, aiming for 75. Price action was muted, as shares hovered around 63.6 despite the bullish outlook.

VTRS

Jan 28, 2026

Target

$12.00

Current

$17.86

Performance

37.70%

On Jan 28, 2026, David Amsellem published a Neutral outlook on VTRS, with a target of 12. The Hold call missed some of the bullish momentum as shares advanced toward 12.

AXSM

Jan 16, 2026

Target

$223.00

Current

$234.20

Performance

32.11%

David Amsellem on Jan 16, 2026 assigned AXSM a Overweight rating, with a price target of 223. The Buy call aligned well with market performance, producing a gain of 32.11%.

FENC

Jan 09, 2026

Target

$18.00

Current

$9.94

Performance

27.93%

On Jan 09, 2026, David Amsellem reaffirmed FENC with a Overweight rating, targeting 18. The recommendation was supported by strong follow-through as the stock rose from 9.94 to 9.94.

ESPR

Nov 25, 2025

Target

$9.00

Current

$3.18

Performance

-13.82%

ESPR was rated Overweight by David Amsellem on Nov 25, 2025, with a price objective of 9. This case shows how bullish projections can fail, with the stock now below 3.18.

XERS

Nov 07, 2025

Target

$8.00

Current

$8.24

Performance

10.90%

On Nov 07, 2025, David Amsellem initiated coverage on XERS with a Neutral rating and target of 8. The Hold stance underestimated the stock’s strength as it gained 10.90%.

AQST

Nov 07, 2025

Target

$8.00

Current

$3.76

Performance

-37.75%

David Amsellem issued a Overweight recommendation for AQST on Nov 07, 2025, price target set at 8. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

INDV

Oct 31, 2025

Target

$41.00

Current

$40.99

Performance

39.56%

On Oct 31, 2025, INDV was evaluated by David Amsellem, who gave a Overweight rating and target of 41. This case illustrates how a timely bullish rating can translate into tangible gains of 39.56%.

AMRX

Oct 31, 2025

Target

$13.00

Current

$18.76

Performance

73.38%

David Amsellem rated AMRX as Overweight on Oct 31, 2025, setting a price target of 13. The call has proven timely, with shares rising 73.38% toward the price target of 13.

SUPN

Oct 09, 2025

Target

$65.00

Current

$47.73

Performance

-3.60%

On Oct 09, 2025, SUPN was given a Overweight rating by David Amsellem, with a target price of 65. The stock traded sideways with a -3.60% move, keeping the bullish thesis unresolved.

SAGE

Jun 17, 2025

Target

$8.50

Current

$8.68

Performance

-4.82%

SAGE received a Neutral rating from David Amsellem on Jun 17, 2025, aiming for 8.5. Shares remained flat at 8.68, aligning with the neutral rating.

OPTN

Mar 21, 2025

Target

$9.00

Current

$9.60

Performance

4.92%

On Mar 21, 2025, David Amsellem published a Neutral outlook on OPTN, with a target of 9. Sideways action left the Hold view intact, with no major move since 9.6.

COLL

Feb 04, 2025

Target

$36.00

Current

$35.90

Performance

16.07%

David Amsellem on Feb 04, 2025 assigned COLL a Neutral rating, with a price target of 36. Shares outperformed expectations, climbing 16.07% despite the neutral view.

ITCI

Jan 14, 2025

Target

$132.00

Current

$131.87

Performance

3.92%

On Jan 14, 2025, David Amsellem reaffirmed ITCI with a Neutral rating, targeting 132. The neutral call matched muted market action of 3.92%.

AVDL

Jan 10, 2025

Target

$13.00

Current

$21.64

Performance

173.92%

AVDL was rated Overweight by David Amsellem on Jan 10, 2025, with a price objective of 13. A bullish response from the market helped close the gap of -8.64 to the target.

ANIP

Oct 11, 2024

Target

$68.00

Current

$81.04

Performance

41.83%

On Oct 11, 2024, David Amsellem initiated coverage on ANIP with a Overweight rating and target of 68. The stock’s climb of 41.83% since the call highlights the foresight in the rating.

BHC

Aug 02, 2024

Target

$3.00

Current

$4.52

Performance

-19.72%

David Amsellem issued a Underweight recommendation for BHC on Aug 02, 2024, price target set at 3. The Sell call exposed risks of betting against momentum, as the stock rallied -19.72%.

PCRX

Jul 03, 2024

Target

$42.00

Current

$26.81

Performance

23.78%

On Jul 03, 2024, PCRX was evaluated by David Amsellem, who gave a Overweight rating and target of 42. This case illustrates how a timely bullish rating can translate into tangible gains of 23.78%.

RVNC

May 10, 2024

Target

$11.00

Current

$3.65

Performance

9.94%

David Amsellem rated RVNC as Overweight on May 10, 2024, setting a price target of 11. The call has proven timely, with shares rising 9.94% toward the price target of 11.

Frequency Asked Questions

Who is David Amsellem?

David Amsellem is an analyst from Piper Sandler specializing in the Healthcare sector.

What is David Amsellem's success rate?

David Amsellem currently has a success rate of +76.69%.

How many ratings has David Amsellem issued?

David Amsellem has issued 47 stock ratings so far.

What is the average return of David Amsellem's calls?

Their stock ratings have generated an average return of +24.05%.

What is David Amsellem's ranking?

David Amsellem is ranked #1831 out of 4745 analysts.

What types of ratings does David Amsellem give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow David Amsellem?

You can follow David Amsellem by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by David Amsellem?

Their latest rating was a Buy on TEVA issued on 2026-07-28.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep